Intellia Therapeutics stock jumps on FDA priority review

Intellia Therapeutics stock is experiencing a significant rally following the announcement of an FDA priority review. This regulatory development has triggered a jump in the company's share price as investors react to the expedited review process. The market surge is directly linked to the FDA's decision to prioritize the evaluation of the company's therapeutic candidate, leading to increased investor confidence and a positive trend in the trading performance of Intellia Therapeutics shares today.